AZURRX BIOPHARM (AZRX)
(Delayed Data from NSDQ)
$2.55 USD
+0.05 (2.11%)
Updated May 3, 2019 03:59 PM ET
After-Market: $2.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Entero Therapeutics, Inc. [AZRX]
Reports for Purchase
Showing records 1 - 20 ( 134 total )
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
To Acquire First Wave Bio - One New Drug Candidate, Several Shots on Goal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Making Progress with the RESERVOIR Trial in COVID-19 GI Infection
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Files IND & Defines Trial Design for Niclosamide in Treating CPI Colitis
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 2 Data of MS1819 Combo Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Positive MS1819/PERT Trial Data, Part 1 of COVID-19 Trial Enrolled
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adds Ukrainian Sites for Phase 2 Trial of Niclosamide in GI COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 GI Infections Study Dosing Started; Adjusting PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiates Phase 2 Trial With Niclosamide for COVID-19 GI Infection
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dilution Ahead - Files a $150M Shelf & a $50M ATM
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Recent Positive MS1819 Interim Combination Rx Data, Cash Thru 2021
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Entero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Data from MS1819 Combo Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y